Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 3 1

Status

Completed 3Withdrawn 1

Sponsor Class

INDUSTRY 3NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 8Other hematologic neoplasm 7Thoracic 4Dermatologic 2Sarcoma 1Plasma cell 1Myeloid 1

Conditions

Small Cell Lung Carcinoma 3Lung Neoplasms 1

Interventions

Carboplatin 1174Cisplatin 891Pemetrexed 847pembrolizumab 626Paclitaxel 609Docetaxel 539Gemcitabine 428Radiotherapy 393Erlotinib Hydrochloride 381Nivolumab 344Bevacizumab 337Etoposide 297durvalumab 264Drug Therapy 260osimertinib 237atezolizumab 225Radiosurgery 196Gefitinib 186Vinorelbine 149Magnetic Resonance Spectroscopy 132Ipilimumab 129130-nm albumin-bound paclitaxel 125Cetuximab 113Blood Specimen Collection 106anlotinib 105tislelizumab 103Topotecan 103Specimen Handling 102Surgical Procedures, Operative 101Cyclophosphamide 101

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
obatoclax × Thoracic × Clear all
NCT00405951 2016-07-21

Safety and Efficacy of Obatoclax Mesylate (GX15-070MS)in Combination With Docetaxel for the Treatment of Non-Small Cell Lung Cancer

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 1/2 Completed
47 enrolled
Thoracic

Lung Neoplasms

NCT00682981 2016-07-21

A Phase I/II Study of Carboplatin and Etoposide With or Without Obatoclax in Extensive-stage Small Cell Lung Cancer (ES-SCLC)

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 1/2 Completed
218 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT00521144 2015-05-05

Obatoclax Mesylate and Topotecan Hydrochloride in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer or Advanced Solid Tumors

National Cancer Institute (NCI)

Phase 1/2 Completed
22 enrolled 9 charts
Thoracic

Small Cell Lung Carcinoma

NCT01563601 2012-08-15

Efficacy and Safety of Obatoclax Mesylate in Combination With Carboplatin and Etoposide Compared With Carboplatin and Etoposide Alone in Chemotherapy-Naive Patients With Extensive-Stage Small Cell Lung Cancer

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 3 Withdrawn
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡